105.6 million voting rights were listed for Cellectis as of Oct. 31.

Cellectis reported 100.7 million shares and 105.6 million voting rights on Euronext Growth as of Oct. 31, according to a regulatory filing. The company provided contact details for media and investor relations.

Original reporting
Published Nov 4, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$CLLS
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Why it matters

The disclosed voting rights update informs shareholders of the current equity base, which can affect per-share metrics and dilution expectations.

02

Market read

A routine capital structure filing with modest trading relevance.

03

What to watch

Potential future equity offerings or conversions could further affect dilution.

Relevance 5/10Novelty 6/10Timing: today

Background

Cellectis is a French gene-editing biotech listed on Euronext Paris.

Market effects

Minor impact on biotech sector valuations due to updated share count.

Limited to French market where Cellectis trades.

Low global relevance.

Counterpoint

Investors may view the higher voting rights as a sign of upcoming financing or strategic moves.

Key entities

  • Cellectis

    Gene-editing biotech firm.

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$CLLSMed

What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis (CLLS) reported Q3 earnings, highlighting HEAL-201's potential in reducing PCSK9 levels and plans for a Phase 1 trial. The company expects to cut global headcount by up to 70% in 2026-2027. Revenues fell to $19.9M from $67.4M YoY, while R&D expenses rose to $108.8M. Cash reserves were $149M as of Sept. 30, down from $211M at the end of 2025.

$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.